Business Context and Reporting Period
Company: Clarivate Plc
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: Clarivate is a global provider of transformative intelligence supporting the innovation lifecycle across three segments: Academia & Government (A&G), Intellectual Property (IP), and Life Sciences & Healthcare (LS&H). In February 2026, the Company announced it is pursuing a sale of its LS&H segment to focus on A&G and IP businesses and reduce leverage.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $585.5 million | $593.7 million |
| Net Income (Loss) | $(40.2) million | $(103.9) million |
| Adjusted EBITDA | $241.2 million | $233.2 million |
| Adjusted EBITDA Margin | 41.2% | 39.3% |
| Operating Cash Flow | $134.7 million | $171.2 million |
| Free Cash Flow | $78.9 million | $110.3 million |
| Total Debt Outstanding | $4,326.8 million | $4,469.9 million |
| Cash and Cash Equivalents | $242.2 million | $354.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 1.4% year-over-year. Subscription revenue grew 2.3% organically, but transactional revenue fell 20.0% due to product group wind-downs in A&G and LS&H segments.
- Profitability Improvement: Net loss narrowed significantly from $103.9 million to $40.2 million, driven by a 51% reduction in restructuring costs ($12.0 million vs. $24.7 million) and a $28.1 million swing in other operating income due to favorable foreign exchange impacts.
- Debt Reduction: The Company redeemed $100.0 million of Senior Secured Notes due 2026 in January 2026 and repurchased portions of 2028 and 2029 notes in March 2026, resulting in a net gain of $3.8 million.
- Share Repurchases: The Company repurchased 7.0 million shares for $18.1 million in Q1 2026, leaving $257.4 million remaining under its $500.0 million authorization.
Guidance, Outlook, and Risks
- Strategic Divestiture: Management is actively discussing the sale of the LS&H segment. Proceeds are expected to strengthen the balance sheet, though no transaction is guaranteed.
- Value Creation Plan: The Company continues its restructuring program approved in late 2024, expecting approximately $13 million in additional costs primarily in 2026.
- Key Performance Indicators: Organic Annualized Contract Value (ACV) grew 1.6% year-over-year. The annual renewal rate remained stable at 92.5%.
- Risks: Significant risks include the uncertainty of the LS&H sale, ongoing securities class action litigation regarding prior accounting errors and internal controls, exposure to foreign currency fluctuations, and dependence on third-party data sources.
Investor Verification Checklist
- Verify the status and timeline of the proposed Life Sciences & Healthcare (LS&H) segment divestiture.
- Monitor the progress of the securities class action lawsuits filed in 2022 regarding internal controls and financial reporting.
- Assess the impact of product group wind-downs on future transactional revenue streams in A&G and LS&H.
- Review the Company's ability to maintain high renewal rates (92.5%) amidst competitive pressures and AI regulation risks.
- Track debt reduction progress and interest expense trends following the recent debt repurchases and redemptions.